Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)
11. November 2024 16:35 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member of the Roche Group,...
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr)
04. Oktober 2024 07:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Beigene for Tevimbra® (tislelizumab),...
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations
30. August 2024 07:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE™...
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for VORANIGO® (vorasidenib)
12. August 2024 07:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Servier Pharmaceuticals, as a specialty pharmacy partner for...
Onco360® Has Been Selected as a National Specialty Pharmacy for crovalimab-akkz
05. August 2024 08:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Genentech, a member of the Roche Group, to be in the pharmacy...
CORRECTION -- Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
16. Juli 2024 17:18 ET
|
Onco360 Oncology Pharmacy
In a release issued under the same headline on July 12, 2024 by Onco360 Oncology Pharmacy, please note the change to “infusion” that was made in the first sentence and decreased neutrophils to 92%...
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
12. Juli 2024 07:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., July 12, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Geron Corporation for...
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation
29. April 2024 07:30 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., April 29, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA™...
Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)
08. April 2024 16:35 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for...
Onco360® Celebrates Excellent Patient Care, Reflected by Impressive Net Promoter Score
14. März 2024 16:45 ET
|
Onco360 Oncology Pharmacy
LOUISVILLE, Ky., March 14, 2024 (GLOBE NEWSWIRE) -- This year, Onco360®, the nation’s leading independent specialty oncology pharmacy, celebrates excellent service and care that resulted in...